The outcomes are investigating changes of conventional biomarkers for AD: Aβ42, total tau (t-tau), and 181-phosphorylated tau (p-tau) in CSF; amyloid deposition as measured by 11C-Pittsburgh compound B positron emission tomography (PIB-PET): and HMW Aβ oligomers as measured with our originally developed ELISA [16]. Here, MAPT is linked to Alzheimer disease.